Effect of OVS1 Monoclonal Antibody as Targeted Ovarian and Breast Cancer TherapyP. Moongkarndi,* N. Jaisupa, S. Jongsomboonkusol, S. Kaslungka, N. Sengpanich, W. Samosorn, N. Kosem and N. Neungton
-
Cancer is ranked among the top three causes of death in Thailand. The research has been focused to improve the diagnosis and treatment of cancers. Monoclonal antibodies could become one of the major tools to achieve the satisfied outcome. OVS1 monoclonal antibody (MAb) produced against ovarian cancer was used to identify the mucinous cystadenocarcinoma antigen as a tumor marker secreted in serum. Since breast and ovarian cancers shared various associate markers, the potential of OVS1 MAb in ovarian and breast cancer treatments was determined. MTT assay was employed to measure the cytotoxicity against breast (BT549), ovarian (SKOV3) and endothelial (ECV304) cell lines. Paclitaxel, an anti-tumor drug, and ?-mangostin, a natural purified constituent from Garcinia mangostana pericarp, were tested as MAb-drug conjugation. The binding efficiency of OVS1-?-mangostin to the cancer cells was monitored by fluorescein-5-isothiocyanate (FITC). Furthermore, the apoptosis of cancer cell lines was examined using fluorimetric assay and confirmed by DNA fragmentation in gel electrophoresis. The ED50 of ?-mangostin were 3.5 and 3.4 µg/ml, while the ED50 of MAb-?-mangostin conjugation (MAb-drug conjugation) were 29.6 and 42.8 µg/ml against SKOV3 and ECV304, respectively. Although the ED50 of MAb-drug (?-mangostin) conjugation was higher than that of ?-mangostin alone, the binding efficiency and specificity of MAb-?-mangostin to SKOV3 cancer cells were satisfactory as monitored using FITC. Furthermore, the ED50 of MAb-?-mangostin conjugation against SKOV3 cancer cell showed significant lower value than that against ECV304 endothelial cell line. This study supported the potential application of MAb-drug or
Keyword:
MAb-drug conjugation, α-mangostin, OVS1 MAb, paclitaxel, targeted cancer therapy
Download full paper (PDF File size: 255.90 KB.)
|
